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Abstract
Background: Sleep disturbances are prevalent among older adults and are associated with various individual
diseases. The aim of this study was to investigate whether sleep disturbances are associated with the speed of
multimorbidity development among older adults.
Methods: Data were gathered from the Swedish National study of Aging and Care in Kungsholmen (SNAC-K), an
ongoing population-based study of subjects aged 60+ (N = 3363). The study included a subsample (n = 1189)
without multimorbidity at baseline (< 2 chronic diseases). Baseline sleep disturbances were derived from the
Comprehensive Psychiatric Rating Scale and categorized as none, mild, and moderate–severe. The number of
chronic conditions throughout the 9-year follow-up was obtained from clinical examinations. Linear mixed models
were used to study the association between sleep disturbances and the speed of chronic disease accumulation,
adjusting for sex, age, education, physical activity, smoking, alcohol consumption, depression, pain, and
psychotropic drug use. We repeated the analyses including only cardiovascular, neuropsychiatric, or musculoskeletal
diseases as the outcome.
Results: Moderate–severe sleep disturbances were associated with a higher speed of chronic disease accumulation
(ß/year = 0.142, p = 0.008), regardless of potential confounders. Significant positive associations were also found
between moderate–severe sleep disturbances and neuropsychiatric (ß/year = 0.041, p = 0.016) and musculoskeletal
(ß/year = 0.038, p = 0.025) disease accumulation, but not with cardiovascular diseases. Results remained stable when
participants with baseline dementia, cognitive impairment, or depression were excluded.
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Conclusion: The finding that sleep disturbances are associated with faster chronic disease accumulation points
towards the importance of early detection and treatment of sleep disturbances as a possible strategy to reduce
chronic multimorbidity among older adults.
Keywords: Sleep disturbances, Multimorbidity, Aging, Cardiovascular, Neuropsychiatric, Musculoskeletal
Background
Sleep disturbances are a “public health problem,” as a
third of adults report having insufficient sleep [1, 2], and
half of older adults report some type of sleep disturbance
[3]. While the prevalence of diagnosed insomnia dis-
order ranges from 5 to 8%, 20–40% report insomnia,
and up to 50% complain of sleep problems [4, 5]. It has
been estimated that the mean total healthcare costs were
75% higher for groups with moderate and severe insom-
nia compared to those with no insomnia, of a health
plan sample in the USA [6]. Similarly, those with un-
treated insomnia have higher all-cause healthcare
utilization [7], providing evidence for the economic bur-
dens of (undiagnosed/untreated) sleep disturbances.
Chronic sleep disturbances have a range of negative
health consequences, including hypertension, cardiovas-
cular diseases, stroke, obesity, diabetes, migraines, and
mortality [8, 9]. Sleep disturbances are also associated
with an increased risk for dementia [10, 11], cognitive
impairment [12–14], and depressive symptoms [15, 16].
Another important consequence of sleep disturbances is
daytime sleepiness/drowsiness, which is associated with
falls, death, and accidents [17, 18]. In a National Sleep
Foundation survey, the frequency of sleep problem re-
ports among older adults was 53% among those with no
medical condition and escalated up to 80% among those
with 4+ medical conditions, demonstrating the need for
further investigations [18, 19]. Similarly, insomnia was
associated with multiple medical and psychiatric comor-
bidities in a large analysis of Medicare beneficiaries
(USA) [7].
To understand the broad implications of chronic sleep
disturbances, it is important to simultaneously investi-
gate the associations between sleep disturbances and
multiple health outcomes. Multimorbidity refers to the
coexistence of two or more chronic medical conditions
in an individual [20]. Although multimorbidity is the
norm among older adults [21, 22], there are inter-
individual differences in the speed of multimorbidity de-
velopment and progression.
Cross-sectional studies showed that short sleep dur-
ation, feelings of drowsiness, and difficulties sleeping
were associated with multimorbidity [23, 24]. In a
multi-national cross-sectional study, a linear dose-
dependent association was found between the number
of chronic conditions and sleep disturbances [25].
Findings from a US middle-aged sample showed that
among several health-promoting behaviors, only sleep
and physical activity were associated with multimor-
bidity [26]. Sex differences have also been demon-
strated, including differences in the relationship
between sleep disturbances and commonly co-
occurring chronic conditions [27]. The association be-
tween sleep disturbances and multimorbidity may be
bidirectional. For example, one study showed that the
number of physical conditions at baseline was associ-
ated with incident insomnia two years later [28].
The aim of this study was to investigate the association
between sleep disturbances and the speed of multimor-
bidity development, a proxy for loss of resilience and
multisystem homeostatic dysregulation in older adults
[29, 30].
Methods
Study design and population
The study population was derived from the Swedish
National study of Aging and Care in Kungsholmen
(SNAC-K), an ongoing population-based study, which
enrolled adults aged 60 years and older living in the
community or in institutions in the Kungsholmen dis-
trict of Stockholm between 2001 and 2004 [31]. A total
of 4590 people from 11 age cohorts (60, 66, 72, 78, 81,
84, 87, 90, 93, 96, and ≥ 99 years) were randomly invited
to participate in the study. Finally, 3363 accepted to par-
ticipate in the baseline examination (73.3% participation
rate). Follow-up assessments are performed every
six years for younger participants (60–78 years) and
every three years for older participants (≥ 78 years). In
the current study, we included a subsample of 1189 par-
ticipants without multimorbidity at baseline (i.e., < 2
chronic disease) and with data for the main exposure.
SNAC-K participants undergo a comprehensive clin-
ical and functional assessment by trained personnel at
baseline and follow-ups. Data on past medical history
and vital status were also available through the National
Patient Register and the Swedish Death Register.
Ethics, consent, and permissions
SNAC-K was approved by the Regional Ethical Review
Board in Stockholm in Sweden. Written informed con-
sent was collected from all participants or, if the
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participant was not capable of providing such consent, it
was obtained from a proxy.
Multimorbidity assessment
The total number of chronic conditions at baseline and
at the follow-ups was operationalized according to the
comprehensive list proposed by Calderon-Larrañaga
et al., described elsewhere [32]. All the diagnoses were
coded according to the International Classification of
Diseases, 10th revision (ICD-10) and then classified as
chronic or not chronic; then, those classified as chronic
were grouped into 60 broader disease categories. Clinical
information, laboratory test results, current treatment,
and data from primary care and hospital medical records
were also used to identify specific chronic conditions.
Chronic conditions considered cardiovascular risk fac-
tors (i.e., hypertension, dyslipidemia, and obesity) were
excluded from the total count consistent with previous
studies [33]. Sleep disorders (ICD-10 codes F510-13 and
G47) were also excluded to avoid exposure–outcome
circularity.
Sleep disturbances
The presence of sleep disturbances at baseline was
assessed by physicians through the Comprehensive
Psychiatric Rating Scale (CPRS), a scale rating the sever-
ity of psychiatric symptoms and observed behavior and
change in symptoms over time [34]. The degree of sleep
disturbances was categorized into three groups accord-
ing to participants’ answers to the CPRS items on sleep:
no sleep disturbances, mild sleep disturbances (grouping
the categories 1–2 “Slight difficulty dropping off to sleep
or slightly reduced, light or fitful sleep”), and moderate–
severe sleep disturbances (grouping the categories 3–4
“Sleep reduced or broken by at least two hours” and 5–6
“Less than two or three hours of sleep”).
Covariates
Education was measured as the highest level of formal
education and was categorized as elementary school,
high school, and university or above. Physical activity
was categorized into three groups of intensity: inad-
equate, health-enhancing, and fitness-enhancing [35].
Smoking habit was categorized as never, former, or
current smoker, and alcohol consumption as never,
light/moderate, and heavy consumption. Body mass
index (BMI) was calculated by dividing weight in
kilograms by the square of height in meters and then
categorized as underweight (< 18.5 kg/m2), normal
weight (18.5–24.9 kg/m2, reference category), overweight
(25–29.9 kg/m2), or obese (≥ 30 kg/m2). We created a
variable identifying people taking psychotropic drugs
(i.e., anxiolytics, hypnotics, sedatives, antipsychotics, and
antidepressants). The self-reported presence of any pain
in the last month before baseline was also considered.
Depressive symptoms were assessed through the Mont-
gomery–Åsberg Depression Scale (MADRS) [36], a 10-
item subscale driven from the CPRS rating depressive
symptom intensity, frequency, and duration. The MADR
S scores range between 0 and 60, and scores > 9 reflect
the presence of depression [37].
Statistical analyses
The cross-sectionaly associations between baseline
sociodemographic, clinical and lifestyle characteristics
and sleep disturbances were examined using the chi-
square test for proportions and the Kruskal–Wallis test
for continuous variables.
The longitudinal associations between sleep distur-
bances at baseline and the speed of chronic disease accu-
mulation throughout the 9-year follow-up were analyzed
through linear mixed models. We included the inter-
action term between time and the main exposure as a
fixed effect. The β coefficients for such interactions can
be interpreted as the effect of each level of sleep disturb-
ance on the average annual increase in the number of
chronic diseases [29, 30]. Random effects were defined
for the intercept and slope, unstructured covariance was
assumed, and restricted maximum likelihood estimation
was applied. Models were adjusted for all covariates in a
cumulative manner: (1) sex, age, and education; (2)
additionally by physical activity, smoking, and alcohol
consumption; and (3) additionally by the presence of de-
pression (MADRS score > 9), presence of any pain, use
of psychotropic medication, and presence of one chronic
disease at baseline. Three-way interactions between age,
sex, or psychotropic drug use and sleep disturbances ×
time were tested. To investigate the role of sleep distur-
bances on the development of specific clusters of
chronic diseases [38], we repeated the analyses including
only cardiovascular, neuropsychiatric, and musculoskel-
etal diseases as the outcome in three different models.
Last, we explored if specific types of sleep disturbances
were associated with multimorbidity development, either
among participants reporting any type of sleep distur-
bances or in the whole study sample.
Sensitivity analyses
To evaluate if the associations were driven by any
specific chronic conditions either at baseline or at
follow-ups, we first compared the distribution of the
most prevalent cardiovascular, neuropsychiatric, and
musculoskeletal chronic diseases by the presence and se-
verity of sleep disturbances at baseline using the chi-
square test. Second, we repeated the analyses concerning
cardiovascular, neuropsychiatric, and musculoskeletal
diseases after removing the three most common chronic
conditions from each group of diseases, one at a time.
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Third, we repeated the analyses excluding those partici-
pants with a diagnosis of dementia or a Mini-Mental
State Examination (MMSE) score < 24 at baseline (n =
13), to avoid exposure measurement error in these par-
ticipants. We also repeated the analyses excluding par-
ticipants with a diagnosis of depression or a MADRS
score > 9 at baseline (n = 43). All analyses were per-
formed using Stata v.14.
Results
The mean age of participants was 67.5 years (SD = 7.9)
and 58% were female (Supplementary Table 1). Those
with missing exposure data (n = 28) were more likely to
be widow and have an elementary education compared
with the study population. Participants with moderate–
severe sleep disturbances were more likely to take
psychotropic drugs, suffer from depressive symptoms,
and self-report pain compared to those with no or mild
disturbances (Table 1). There was also a higher propor-
tion of women among participants with moderate–se-
vere disturbances, and this group had higher levels of
inadequate physical activity (Table 1). Among the popu-
lation with sleep disturbances, the three most prevalent
types of disturbances were waking up during the night
(86.5%), waking up early (51.6%), and problems to fall
asleep (39.1%) (Table 2).
Moderate–severe sleep disturbances at baseline were
associated with a higher speed of chronic disease accu-
mulation throughout the 9-year follow-up, and the
direction and magnitude of the association remained
stable regardless of potential confounders (Table 3). No
significant interactions were found with age, sex, or
psychotropic drug use. When focusing on specific
groups of chronic diseases, a significant positive associ-
ation was found between moderate–severe sleep distur-
bances and neuropsychiatric and musculoskeletal disease
accumulation, but not with cardiovascular diseases
(Table 4, Fig. 1).
When focusing on specific types of sleep disturbances,
“feeling tired more than 2 hours during the day” was
consistently associated with the rate of total, neuro-
psychiatric, and musculoskeletal disease accumulation
(Supplementary Tables 2A and B).
Except for ischemic heart disease and depression and
mood diseases (borderline statistical significance), no
other differences were found in the baseline distribution
of the most prevalent cardiovascular, neuropsychiatric,
and musculoskeletal chronic diseases by presence and
severity of sleep disturbances (Supplementary Table 3).
When the analyses in Table 4 were repeated after re-
moving one condition at a time (only the individual con-
dition specified) from each group of chronic diseases
(Supplementary Table 4), similar findings were obtained.
The one exception was musculoskeletal disease; when
osteoarthritis and other degenerative joint diseases were
removed, the association was no longer significant. Re-
sults remained the same when participants with a base-
line diagnosis of dementia or MMSE < 24 were excluded
from the study sample (Supplementary Table 5). When
participants with depression and mood diseases or a
MADRS score > 9 were excluded, the direction of the as-
sociation between moderate–severe sleep disturbances
and the rate of chronic disease accumulation remained
the same, even if it did not reach statistical significance
(Supplementary Table 6).
Discussion
This study sought to investigate the association between
sleep disturbances and the speed of multimorbidity
development in older adults. Results showed that mod-
erate–severe sleep disturbances at baseline were inde-
pendently associated with a higher speed of chronic
disease accumulation during the 9-year follow-up. With
regard to specific groups of chronic diseases, a signifi-
cant positive association was found between moderate–
severe sleep disturbances and neuropsychiatric and
musculoskeletal disease accumulation, but not with
cardiovascular diseases. To the best of our knowledge,
this is the first study to longitudinally investigate sleep
and speed of multimorbidity development after a long
follow-up duration in a large population-based study.
Considering that this is the first study to show such
associations, direct comparisons cannot be made with
previous literature.
Our finding on the association between sleep distur-
bances and accumulation of neuropsychiatric diseases
supports previous cross-sectional results from nationally
representative samples, where of several conditions, de-
pression was the only one consistently associated with
sleep disturbances [25]. In a Korean study, baseline in-
somnia was associated with incident depression after
two years [28]. In our study, even when depression was
removed from the analyses, the associations remained
robust. This may highlight the additional strong associa-
tions between sleep disturbances and dementia and mi-
graine and facial pain syndromes. Our findings are
consistent with studies showing that sleep disturbances
are associated with dementia risk [10, 11]. This study
additionally supports a recent meta-analysis showing
that obstructive sleep apnea is associated with cerebro-
vascular diseases [39]. The current findings provide fur-
ther evidence regarding the association between sleep
disturbances and incidence of neuropsychiatric condi-
tions, but also a faster accumulation of neuropsychiatric
conditions.
Regarding our finding on the association between
sleep disturbances and speed of musculoskeletal disease
accumulation, when osteoarthritis and other
Sindi et al. BMC Medicine          (2020) 18:382 Page 4 of 10
Table 1 Baseline distribution of sociodemographic, clinical, and lifestyle characteristics by presence and severity of sleep
disturbances
No disturbances, n = 955 Mild disturbances¥, n = 175 Moderate–severe disturbances§, n = 59 p value*
Age, mean (SD) 67.6 (7.8) 67.9 (8.3) 65.9 (8.1) 0.504
Sex, % (n) 0.032
Female 56.3 (538) 64.0 (112) 69.5 (41)
Male 43.7 (417) 36.0 (63) 30.5 (18)
Education, % (n) 0.332
Elementary 10.4 (99) 8.0 (14) 17.0 (10)
High school 46.1 (439) 44.6 (78) 39.0 (23)
University 43.5 (414) 47.4 (83) 44.0 (26)
Physical activity, % (n) 0.001
Inadequate 18.2 (174) 16.0 (28) 33.9 (20)
Health-enhancing 50.3 (480) 57.7 (101) 54.2 (32)
Fitness-enhancing 31.5 (301) 26.3 (46) 11.9 (7)
Smoking, % (n) 0.214
Never 43.3 (410) 43.7 (76) 42.4 (25)
Former 37.7 (358) 43.1 (75) 45.8 (27)
Current 19.0 (180) 13.2 (23) 11.8 (7)
Alcohol, % (n) 0.097
Never 20.6 (195) 20.6 (36) 33.8 (20)
Light–moderate 61.8 (589) 57.7 (101) 49.2 (29)
Heavy 17.6 (169) 21.6 (38) 17.0 (10)
BMI, % (n) 0.380
Underweight 1.0 (9) 0.0 (0) 1.7 (1)
Normal weight 45.3 (426) 47.7 (83) 39.0 (23)
Overweight 42.3 (398) 37.3 (65) 42.3 (25)
Obesity 11.4 (107) 15.0 (26) 17.0 (10)
Psychotropic drugsa, % (n) 7.1 (68) 22.3 (39) 25.4 (15) < 0.001
Depressionb, % (n) 1.1 (10) 5.8 (10) 14.3 (8) < 0.001
Painc, % (n) 22.8 (217) 34.5 (60) 47.5 (28) < 0.001
*Obtained through the chi-squared test or the Kruskal–Wallis test, as appropriate
aPsychotropic drugs include anxiolytics, hypnotics, sedatives, antipsychotics, and antidepressants
bDepression defined according to the Montgomery–Åsberg Depression Rating Scale (MADRS); scores > 9 indicate depression
cSelf-reported presence of any pain in the last month
¥Categories 1–2 “Slight difficulty dropping off to sleep or slightly reduced, light or fitful sleep” of the CPRS question on sleeping problems
§Categories 3–4 “Sleep reduced or broken by at least two hours” and 5–6 “Less than two or three hours of sleep” of the CPRS question on sleeping problems
Table 2 Type of disturbances among subjects reporting sleep disturbances in the study sample
Total,
n = 234
< 78 years ≥ 78 years
Male, n = 70 Female, n = 123 Male, n = 11 Female, n = 30
Problems to fall asleep, % (n) 39.1 (90) 30.9 (21) 42.5 (51) 45.5 (5) 43.3 (13)
Waking up during night, % (n) 86.5 (199) 89.7 (61) 82.6 (100) 90.9 (10) 93.3 (28)
Not being able to fall back asleep, % (n) 38.4 (84) 27.7 (18) 43.4 (49) 27.3 (3) 46.7 (14)
Waking up too early, % (n) 51.6 (116) 51.5 (34) 52.1 (62) 45.5 (5) 51.7 (15)
Feeling tired > 2 h during the day, % (n) 4.4 (10) 6.0 (4) 4.1 (5) 9.1 (1) 100.0 (30)
Taking sleeping drugs, % (n) 28.6 (65) 16.4 (11) 30.0 (36) 27.3 (3) 50.0 (15)
Total sleep duration < 6 h*, % (n) 27.1 (61) 27.3 (18) 25.0 (30) 27.3 (3) 35.7 (10)
*Defined as short sleep duration by Gildner et al. [9]
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degenerative joint diseases were removed from the ana-
lyses, the associations were no longer significant, sug-
gesting a central role of these conditions. A recent
systematic review and meta-analysis has shown that hav-
ing osteoarthritis was associated with the presence of
other chronic conditions and multimorbidity in a dose-
dependent manner [40]. Our results add to this litera-
ture by highlighting the role of osteoarthritis and degen-
erative joint disease in the associations between sleep
disturbances and musculoskeletal disease accumulation.
These findings are also consistent with cross-sectional
results from Brazil demonstrating a U-shaped associ-
ation; both short sleep and long sleep duration were as-
sociated with rheumatism/arthritis/arthrosis and
osteoporosis [23]. Short sleep duration was also associ-
ated with back pain problems. Similarly, in the afore-
mentioned multi-national study, sleep disturbances were
associated with arthritis [25]. Another cross-sectional
study among older adults in Germany showed that in-
somnia and daytime tiredness were associated with joint
diseases [27]. Increased pain and inflammation are
proposed as central mechanisms in these associations,
and fatigue may also play a role [41, 42].
In the current study, although the lack of association be-
tween sleep disturbances and cardiovascular disease accu-
mulation may appear to contradict previous findings,
comparisons are in fact non-feasible, considering the
cross-sectional study designs, differences in age groups,
definitions of multimorbidity, sleep disturbance measure-
ments, and non-included potential confounders (e.g.,
BMI, hypnotics, education, smoking, alcohol consump-
tion, exercise) in the previous studies reporting positive
associations [9, 23, 25, 27]. These methodological differ-
ences may contribute to the observed differences. More-
over, in our study, the non-significant association between
sleep disturbances and cardiovascular disease may reflect
a selection bias; in this sample of older adults, those with
cardiovascular diseases may have not participated in this
study or its follow-up assessments due to earlier adverse
outcomes (e.g., mortality and disability). Also, participants
with cardiovascular diseases tend to have other coexisting
chronic conditions [43] and may have been excluded from
Table 3 Association between sleep disturbances at baseline and rate of chronic diseases accumulation throughout the 9-year
follow-up
Model 1 Model 2 Model 3
ß (SE) p value ß (SE) p value ß (SE) p value
No disturbances Ref Ref Ref
Mild disturbances¥ 0.018 (0.032) 0.574 0.019 (0.032) 0.539 0.022 (0.032) 0.496
Moderate–severe disturbances§ 0.145 (0.053) 0.006 0.147 (0.053) 0.005 0.142 (0.054) 0.008
ß coefficients for the interaction term between time and the exposure, obtained through linear mixed models.
Model 1: adjusted by sex, age, and education level
Model 2: adjusted additionally by physical activity, smoking, alcohol consumption, and BMI
Model 3: adjusted additionally by the presence of depression (MADRS score > 9), presence of any pain, psychotropic medication, and presence of one chronic
disease at baseline
¥Categories 1–2 “Slight difficulty dropping off to sleep or slightly reduced, light or fitful sleep” of the CPRS question on sleeping problems
§Categories 3–4 “Sleep reduced or broken by at least two hours” and 5–6 “Less than two or three hours of sleep” of the CPRS question on sleeping problems
Table 4 Association between sleep disturbances at baseline and rate of cardiovascular (CV), neuropsychiatric (NP), and
musculoskeletal (MSK) chronic disease accumulation throughout the 9-year follow-up
CV diseases NP diseases MSK diseases
ß (SE) p value ß (SE) p value ß (SE) p value
No disturbances Ref Ref Ref
Mild disturbances¥ − 0.012 (0.011) 0.267 0.008 (0.009) 0.419 − 0.003 (0.010) 0.735
Moderate–severe disturbances§ 0.001 (0.018) 0.995 0.041 (0.016) 0.008 0.038 (0.017) 0.025
ß coefficients for the interaction term between time and the exposure, obtained through linear mixed models. Models adjusted by sex, age, education level,
physical activity, smoking, alcohol consumption, BMI, presence of depression (MADRS score > 9) except for the model with NP diseases as the outcome, presence
of pain, psychotropic medication, and presence of one chronic disease at baseline. Cardiovascular diseases: ischemic heart disease, heart failure, atrial fibrillation,
cerebrovascular disease, cardiac valve diseases, bradycardias or conduction diseases, peripheral vascular disease, and other cardiovascular diseases.
Neuropsychiatric diseases: depression and mood diseases, dementia, neurotic or stress-related and somatoform diseases, migraine and facial pain syndromes,
peripheral neuropathy, Parkinson or parkinsonism, epilepsy, schizophrenia and delusional diseases, multiple sclerosis, other psychiatric or behavioral diseases, and
other neurological diseases. Musculoskeletal diseases: dorsopathies, inflammatory arthropathies, osteoarthritis and other degenerative joint diseases, osteoporosis,
and other musculoskeletal and joint diseases
¥Categories 1–2 “Slight difficulty dropping off to sleep or slightly reduced, light or fitful sleep” of the CPRS question on sleeping problems
§Categories 3–4 “Sleep reduced or broken by at least two hours” and 5–6 “Less than two or three hours of sleep” of the CPRS question on sleeping problems
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our study sample, which may have prevented us from
finding such an association.
The results showed that there were no significant in-
teractions between sleep disturbances and age or sex. A
previous study did find sex-specific associations; insom-
nia and specific insomnia symptoms were associated
with multimorbidity among women, but not among men
[27]. This study differed from the current one as it was
cross-sectional and it did not adjust for depression,
chronic diseases, and pain. Also, the sample was slightly
older in age with lower education levels. Considering the
previously reported sex differences in sleep, this topic
warrants further investigation among older adults [44].
Several mechanisms may underlie the associations ob-
served. First, an important mechanism underlying neuro-
psychiatric and cardiovascular conditions is dysregulations
in the hypothalamic–pituitary–adrenal (HPA) axis [45, 46],
which are also implicated in sleep disturbances. Poor sleep
quality enhances the reactivity of the HPA axis and is asso-
ciated with higher daytime cortisol levels [47, 48], and al-
tered cortisol awakening response [49]. The relationship
between sleep disturbances and HPA axis dysregulations
may be bidirectional, as HPA axis hyperactivation is also as-
sociated with poor sleep [50]. Second, sleep disturbances
are connected with dysregulations in inflammatory
markers. For example, sleep disturbances are associated
with higher levels of C-reactive protein (CRP) and
interleukin-6 (IL-6) [51], which are also commonly elevated
in musculoskeletal and neuropsychiatric diseases [52, 53],
and among people with a fast accumulation of chronic dis-
eases [54]. These mechanisms may also impact serotonin, a
neurotransmitter that plays a role in regulating sleep-wake
states, and also regulates mood and tends to be depleted
in depression, representing an important component
in the pathophysiology of the disorder [55–57]. An-
other potential mechanism may be through the
neuropeptide orexin, which regulates sleep-wake cy-
cles and the circadian rhythm and plays a role in cog-
nitive function and the cardiovascular system [58].
Orexin receptor antagonists have been investigated
for their potential therapeutic effects for the treat-
ment of insomnia [59]. Sleep disturbances are also as-
sociated with compromises in metabolic health and
can increase the risk for obesity, dyslipidemia, hyper-
tension, and impaired glucose metabolism, all of
which increase the risk for cardiovascular conditions
[60]. Lifestyle factors, beyond those taken into ac-
count in our models (e.g., changes in appetite, diet,
and polypharmacy), which also increase cardiometa-
bolic risk and degrade sleep quality [60–62].
This study has a few limitations. The measure of sleep
was self-reported and measured at a single time point.
Objective measures of chronic sleep disturbances may
provide more reliable data. While the current study in-
vestigates sleep in late life and its association with multi-
morbidity, evidence from other studies highlights the
importance of midlife sleep and adverse outcomes [11,
14, 63]. Regarding the feelings of tiredness during the
day, we could not examine the source of tiredness, as
this additional information was not collected. We also
did not have clinical measures of sleep apnea, which is






















































Fig. 1 Predicted number of neuropsychiatric (NP) and musculoskeletal (MSK) chronic diseases over the 9-year follow-up in relation to the
presence and severity of sleep disturbances at baseline
ß coefficients for the interaction term between time and the exposure, obtained through linear mixed models. Models adjusted by sex, age,
education level, physical activity, smoking, alcohol consumption, BMI, presence of depression (MADRS score > 9) except for the model with NP
diseases as the outcome, presence of pain, psychotropic medication, and presence of any chronic disease. Neuropsychiatric diseases: depression
and mood diseases, dementia, neurotic or stress-related and somatoform diseases, migraine and facial pain syndromes, peripheral neuropathy,
Parkinson or parkinsonism, epilepsy, schizophrenia and delusional diseases, multiple sclerosis, other psychiatric or behavioral diseases, and other
neurological diseases. Musculoskeletal diseases: dorsopathies, inflammatory arthropathies, osteoarthritis and other degenerative joint diseases,
osteoporosis, and other musculoskeletal and joint diseases.
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parameters such as sleep efficiency and sleep latency are
not included. The external validity of the study is limited
because the sample only included healthy participants
from SNAC-K population, which is wealthier than average
in Sweden, and may have better lifestyle and fewer vascu-
lar risk factors (e.g., obesity). Attrition due to mortality
and dropout might have affected the results. Although we
excluded subjects with multimorbidity at baseline, and ad-
justed our models for several confounders, the possibility
of reverse causality or residual confounding cannot be
fully discarded given the potential heterogeneity in sub-
clinical health states leading to multimorbidity. Finally,
sleep disturbances may in fact represent the symptoms of
already established disorders (e.g., depression, arthritis).
These could be the single disorders that people with only
one disease suffer from (who were not excluded from the
study sample) or disorders that were undiagnosed yet at
baseline. In both cases, this could potentially lead to re-
verse causality regarding the associations between sleep
disturbances and multimorbidity.
Despite the limitations, this study has several
strengths. First, this study is population-based, longitu-
dinal, with baseline measures of sleep disturbances in
old age, and a 9-year follow-up. Second, chronic condi-
tions were either objectively measured by physicians
within the SNAC-K study or retrieved in medical health
records, including a wide range of diseases. Third, this
study provides data on the speed of multimorbidity ac-
cumulation, a proxy for the speed of biological aging
[66]. Fourth, individuals with multimorbidity at baseline
were excluded from analyses, which limits the risk of re-
verse causality. Fifth, sleep was measured using a vali-
dated scale including several parameters of sleep
disturbances. Finally, we have adjusted for potential con-
founders including medications.
Sleep disturbances and circadian rhythm disruptions
may be a proxy of biological vulnerability or early disease
stage [67] and therefore may help identify individuals with
potentially worse multimorbidity trajectories. Sleep distur-
bances tend to be chronic, and interventions need to tar-
get a comprehensive range of behavioral/lifestyle factors
that impact sleep. Evidence from randomized controlled
trials offers support for cognitive behavioral therapy for
insomnia (CBT-I) as an effective and comprehensive non-
pharmacological approach [61, 62, 68]. Considering the
potential side effects of pharmacological treatments, they
are recommended as a last resort [61].
Conclusion
In conclusion, for the first time, this study showed that
moderate–severe sleep disturbances were associated
with a higher speed of overall, neuropsychiatric and
musculoskeletal chronic disease accumulation over time.
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